BBIO BridgeBio Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1743881 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY167.3%
TTM net income YoY29.0%
TTM EPS YoY28.0%
Revenue 3-yr CAGR364.6%
Net income 3-yr CAGR—
Margins
Gross margin94.3%
Operating margin-38.5%
Net margin-59.8%
FCF margin-39.1%
EBITDA margin-38.0%
Returns
ROE—
ROA-35.8%
ROIC (approx.)—
Asset turnover0.60x
Leverage & solvency
Liabilities / assets176.5%
Debt / equity—
Current ratio2.09x
Interest coverage-7.13x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $502.08M | $221.90M | $9.30M | $77.65M | $69.72M |
| Cost of revenue | $20.96M | $3.88M | $2.45M | $3.43M | $3.11M |
| Gross profit | $481.11M | $218.02M | $6.86M | $74.21M | $66.60M |
| R&D expense | $451.95M | $506.46M | $455.71M | $399.46M | $451.02M |
| SG&A expense | $531.23M | $288.93M | $150.59M | $143.19M | $192.21M |
| Operating income | -$523.41M | -$592.97M | -$607.37M | -$512.20M | -$576.63M |
| Interest expense | $53.10M | $90.99M | $81.29M | $80.44M | $46.78M |
| Pretax income | -$732.50M | -$542.19M | -$653.25M | -$484.65M | -$586.48M |
| Income tax | $435,000 | $1.15M | $0 | $0 | — |
| Net income | -$724.93M | -$535.76M | -$643.20M | -$481.18M | -$562.54M |
| EBITDA | -$517.98M | -$586.90M | -$600.88M | -$505.43M | -$570.79M |
| EPS (basic) | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 |
| EPS (diluted) | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 |
| Weighted avg. shares (diluted) | 191.53M | 186.08M | 162.79M | 147.47M | 144.36M |
| Balance sheet | |||||
| Cash & equivalents | $570.12M | $681.10M | $375.94M | $376.69M | $393.77M |
| Short-term investments | $17.36M | $0 | $0 | $51.58M | $393.74M |
| Receivables | $139.44M | $4.72M | $1.75M | — | — |
| Inventory | $26.75M | $0 | — | — | — |
| Current assets | $797.75M | $720.69M | $477.59M | $548.85M | $888.86M |
| PP&E, net | $5.37M | $7.01M | $11.82M | $14.57M | $30.07M |
| Intangibles | $28.08M | $23.93M | $26.32M | $28.71M | $44.93M |
| Total assets | $936.02M | $919.34M | $546.38M | $623.04M | $1.01B |
| Current liabilities | $287.97M | $154.40M | $143.84M | $121.43M | $135.07M |
| Long-term debt | $2.01B | $437.34M | $446.44M | $430.99M | $430.75M |
| Total debt | $2.01B | $437.34M | $446.44M | $430.99M | $430.75M |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B |
| Shareholders' equity | -$2.09B | -$1.47B | -$1.35B | -$1.25B | -$870.41M |
| Net debt | $1.44B | -$243.76M | $70.51M | $54.30M | $36.98M |
| Shares outstanding | 194.77M | 190.04M | 175.08M | 150.63M | 147.34M |
| Cash flow statement | |||||
| Operating cash flow | -$445.91M | -$520.73M | -$527.72M | -$419.49M | -$497.93M |
| Capital expenditure | $1.10M | $933,000 | $1.31M | $4.82M | $13.25M |
| Free cash flow | -$447.01M | -$521.66M | -$529.03M | -$424.31M | -$511.18M |
| Investing cash flow | -$24.49M | $60.78M | $54.03M | $453.15M | -$200.83M |
| Financing cash flow | $359.29M | $748.46M | $451.54M | -$13.13M | $736.45M |
| Depreciation & amortization | $5.43M | $6.08M | $6.49M | $6.77M | $5.84M |
| Stock-based compensation | $133.02M | $95.80M | $108.71M | $91.56M | $99.50M |
| Share buybacks | $48.28M | $0 | $0 | $0 | $200.00M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.